Optiscan Imaging has announced an exclusive collaboration with Canadian-based Prolucid Technologies to develop Artificial Intelligence (AI) algorithms and telepathology workflows using its confocal laser endomicroscopy (CLE) technology.
The company said the project, which is anticipated to take 18-24 months, aims to develop software as a medical device (SaMD) using its platform technology.
It said the results will support image collection, processing, and tissue analytics to detect the presence of pre-cancerous and cancerous cells, enabling immediate clinical decision-making.
Optiscan said the partnership with Prolucid forms part of its broader strategy.
CEO and managing director Dr Camile Farah said, “The development of AI algorithms with Prolucid aligns with our vision to be at the forefront of enabling immediate, informed clinical decisions for clinicians using digital microscopy. Our telepathology platform will allow remote diagnosis and assist with the uptake of our imaging platform in addition to opening new revenue streams. We are excited about accelerating our momentum in 2023, and bringing our slide-free, biopsy-free optical technology to the world.”